文献速递免疫规划

含高度纯化病毒颗粒和佐剂的疫苗对豚鼠阴道内攻击同源和异源2型单纯疱疹病毒株提供高水平保护

A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2.
PubMed 文献 · Vaccine · 2019-10-11

在豚鼠生殖器疱疹模型中评估含高度纯化灭活HSV-2颗粒(加或不加重组糖蛋白D)与单磷酰脂质A/铝佐剂配制疫苗的保护效果。3项独立研究显示,接种 consistently 使攻击后第2天阴道HSV-2滴度显著降低3-3.5 Log10,同源和异源攻击后所有疫苗组均完全预防病变形成,部分动物检测不到脱落或潜伏病毒DNA;加入糖蛋白D未增强保护。

要点

  • 豚鼠模型中疫苗使攻击后第2天阴道HSV-2滴度降低3-3.5 Log10。
  • 同源和异源攻击后所有疫苗组完全预防病变形成。
  • 加入糖蛋白D未增强灭活HSV-2颗粒疫苗的保护效果。

核心结论

  • 数据强烈支持进一步开发该高度保护且高度可行的候选疫苗用于人体试验。

研究设计与样本

  • 在豚鼠HSV生殖器模型中评估含高度纯化灭活HSV-2颗粒(加或不加重组糖蛋白D)与单磷酰脂质A/铝佐剂配制疫苗的保护效果,共3项独立研究。

主要发现

  • 接种 consistently 使攻击后第2天阴道HSV-2滴度显著降低3-3.5 Log10。
  • 同源或异源攻击(两株美国分离株)后,所有疫苗组完全预防病变形成,第2天病毒脱落显著降低3 Log10,病毒清除增强,神经节内HSV-2 DNA显著减少,部分免疫动物检测不到脱落(<2 PFU)或潜伏病毒DNA。
  • 第三株异源毒株攻击后,接种完全预防原发和复发病变,原发病毒脱落显著减少,复发脱落天数减少50%,大多数动物神经节和脊髓中检测不到潜伏病毒。
  • 加入糖蛋白D相对于单独灭活HSV-2颗粒未提供增强保护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infection with Herpes Simplex Viruses (HSVs) represents a significant health burden worldwide with HSV-1 and HSV-2 causing genital disease and HSV-2 contributing to human immunodeficiency virus acquisition. Despite great need, there is currently no licensed vaccine against HSV. In this report, we evaluated the protective efficacy of a vaccine containing highly purified, inactivated HSV-2 particles (with and without additional recombinant glycoprotein D) formulated with a monophosphoryl lipid A/Alhydrogel adjuvant in a guinea pig HSV genital model. The key results from 3 independent studies were: (1) vaccination consistently provided significant 3-3.5 Log10 reductions in vaginal HSV-2 titers on day 2 postchallenge; (2) following homologous or heterologous challenge with two U.S. isolates, all vaccine groups showed complete protection against lesion formation, significant 3 Log10 reductions in day 2 virus shedding, enhanced virus clearance, significant reductions in HSV-2 DNA within ganglia, and no detectable shedding (<2 PFU) or latent viral DNA in some immunized animals; (3) following challenge with a third heterologous strain, vaccination provided complete protection against primary and recurrent lesions, significant reductions in primary virus shedding, a 50% reduction in recurrent shedding days, and undetectable latent virus in the ganglia and spinal cords of most animals; and (4) adding glycoprotein D provided no enhanced protection relative to that elicited by the inactivated HSV-2 particles alone. Together, these data provide strong support for further development of this exceedingly protective and highly feasible vaccine candidate for human trials.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bernstein DI, Morello CS, Cardin RD, et al. A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2. Vaccine. 2019. PMID: 31611098. doi:10.1016/j.vaccine.2019.09.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。